This presentation summarizes the business characteristics of Advanced Cell Technology Inc (ACT). It contains forward-looking statements and risk factors that could cause actual results to differ from projections. The document outlines ACT's lead product candidate as an RPE cell therapy for retinal degenerative diseases with massive unmet need. It reviews ACT's GMP manufacturing process, preclinical models demonstrating safety and efficacy, and preliminary positive results from an ongoing Phase I clinical trial in Stargardt's Macular Dystrophy and dry AMD.
RETINA COMPANY SHOWCASE- Aerie PharmaceuticalsHealthegy
Panel Discussion by Aerie Pharmaceuticals at OIS@ASRS 2016.
Participant:
Casey Kopczynski, Chief Scientific Officer- Aerie Pharmaceuticals
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Presentation from OIS@ASCRS 2016
Tom Mitro, President & COO
Video Presentation:
https://www.youtube.com/watch?v=rjLnP6lmRWU&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=29
Public Device & Biopharma Ophthalmology Company Showcase - Adverum Biotechnol...Healthegy
Public Device & Biopharma Ophthalmology Company Showcase - Adverum Biotechnologies at OIS@AAO 2016.
Presenter:
Samuel B. Barone, MD SVP, Clinical Development
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Presentation from OIS@ASCRS 2016
Rajesh K. Rajpal, MD, Chief Medical Officer
Video Presentation:
https://www.youtube.com/watch?v=Wbq-D5kwMUk&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=39
Anterior Segment Company Showcase - Mynosys Cellular DevicesHealthegy
Anterior Segment Company Showcase - Mynosys Cellular Devices at OIS@AAO 2016.
Presenter:
John Hendrick, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Presentation from OIS@ASCRS 2016
James Brandt, MD, Principal Investigator
Video Presentation:
https://www.youtube.com/watch?v=jvIozhPMSQ8&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=30
RETINA COMPANY SHOWCASE- Aerie PharmaceuticalsHealthegy
Panel Discussion by Aerie Pharmaceuticals at OIS@ASRS 2016.
Participant:
Casey Kopczynski, Chief Scientific Officer- Aerie Pharmaceuticals
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Presentation from OIS@ASCRS 2016
Tom Mitro, President & COO
Video Presentation:
https://www.youtube.com/watch?v=rjLnP6lmRWU&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=29
Public Device & Biopharma Ophthalmology Company Showcase - Adverum Biotechnol...Healthegy
Public Device & Biopharma Ophthalmology Company Showcase - Adverum Biotechnologies at OIS@AAO 2016.
Presenter:
Samuel B. Barone, MD SVP, Clinical Development
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Presentation from OIS@ASCRS 2016
Rajesh K. Rajpal, MD, Chief Medical Officer
Video Presentation:
https://www.youtube.com/watch?v=Wbq-D5kwMUk&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=39
Anterior Segment Company Showcase - Mynosys Cellular DevicesHealthegy
Anterior Segment Company Showcase - Mynosys Cellular Devices at OIS@AAO 2016.
Presenter:
John Hendrick, President & CEO
Powered by:
Healthegy
For more ophthalmology innovation
Visit us at www.ois.net
Presentation from OIS@ASCRS 2016
James Brandt, MD, Principal Investigator
Video Presentation:
https://www.youtube.com/watch?v=jvIozhPMSQ8&list=PL1dmdBNnPTZJBhQxPOp0vdNg3s3wtN2yw&index=30
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
World stem cells & regenerative medicine congress, london, may 22, 2013
1. This presentation is intended to present a summary of ACT’s (“ACT”, or “Advanced Cell Technology Inc”, or “the Company”) salient business
characteristics.
The information herein contains “forward-looking statements” as defined under the federal securities laws. Actual results could vary materially.
Factors that could cause actual results to vary materially are described in our filings with the Securities and Exchange Commission.
You should pay particular attention to the “risk factors” contained in documents we file from time to time with the Securities and Exchange
Commission. The risks identified therein, as well as others not identified by the Company, could cause the Company’s actual results to differ materially
from those expressed in any forward-looking statements. Ropes Gray
Cautionary Statement Concerning Forward-Looking Statements
1
LEADING
REGENERATIVE
MEDICINE
May 2013
2. David versus Goliath
is the story of every
emerging regenerative
medicine company in
this room….
3. 3
Structure of Retina
The Retina the light-sensitive
tissue lining the inner surface of
the eye
Retina
4. 4
Life Support to Photoreceptors
Provides nutrients and growth factors
• photoreceptors see no blood
Recycles Vitamin A
• maintains photoreceptor excitability
Detoxifies photoreceptor layer
Maintains Bruch’s Membrane
• natural antiangiogenic barrier
• immune privilege of retina
Absorbs stray light / protects from UV
RPE Layer has
multiple
critical roles
in the
health and
function
of photoreceptors and
the retina as a whole.
5. 5
Life Support to Photoreceptors
Failure of RPE cells
results in many
degenerative diseases
Stargardt’s disease
Myopic Macular Dystrophy
Age-related macular degeneration (AMD)
8. 8
RPE Therapy- Rationale
• Massive unmet medical need
• Small dosage size
– less than 200K cells
• Immune-privileged site
– minimal immunosuppression
• Ease of administration
– no separate device approval
• Unique measuring and observation environment
9. Preclinical Models
9
Injected human RPE cells
repair monolayer
structure in eye
Transplanted cells
engraft and form
correct anatomical
structure
ELOVL4 Mouse model for macular degeneration
11. GMP Process
11
Harvest for
Cryopreservation
ES Cells
EB
Formation RPE isolation P1 P2
0 5 weeks 12 weeks 15 weeks 18 weeks
TEST CASE:
• Spiked with 10 percent hESC
• No hESC’s in harvested cells
Limit of Detection for hESC
0.00008%
3 weeks
EB
Outgrowth
30 Weeks
Differentiation Media is Not
Permissive for hESCs
13. GMP Process
13
Normal female (46 XX) karyotype
of the clinical RPE lot.
Regular Marker and Karyotype
Confirmation
14. GMP Process
14
Cell potency of each lot is assessed by phagocytosis
(critical function in vivo) of fluorogenic bioparticles.
Flow cytometry histogram showing
phagocytosis of pHrodo bioparticles
4°C 37°C
Developed Quantitative Cell
Potency Assays
15. GMP Process
15
y = 0.0141x + 0.0007
0.00
0.50
1.00
1.50
2.00
0 20 40 60 80 100120Absorbanceat475nm
µg/mL Melanin
Pigmentation matters - optimize
time to harvest and cryopreserve
16. GMP process for differentiation and purification of RPE
– Virtually unlimited supply from stem cell source
– Optimized for manufacturing
Ideal Cell Therapy Product
– Centralized Manufacturing
– Small Doses
– Easily Frozen and Shipped
– Simple Handling by Doctor
GMP Process
16
Product Cold Chain is Easily Scaled for Global Sales
ACT Cleanroom Suite
17. Phase I - Clinical Trial Design
17
SMD and dry AMD Trials approved in U.S., SMD Trial approved in U.K.
12 Patients / trial
ascending dosages of 50K, 100K, 150K and 200K cells.
Regular Monitoring - including high definition imaging of retina
50K Cells 100K Cells 150K Cells 200K Cells
Best Vision Inclusion Criteria – First Half
SMD Trial: Hand Motion only, modified to 20/400
Dry AMD Trial: 20/800, modified to 20/400
18. 18
Participation by the leading
retinal surgeons in the world
Jules Stein
(UCLA)
Mass
Eye & Ear
Infirmary
Wills Eye
Institute
Bascom
Palmer Eye
Institute
Moorfields
Eye
Hospital
Edinburgh
Royal
Infirmary
19. Surgical Overview
19
Procedure:
• 25 Gauge Pars Plana Vitrectomy
• Posterior Vitreous Separation
• Subretinal hESC-derived RPE cells
injection
• Bleb Confirmation
• Day Surgery/Sedation only
20. Preliminary Results
20
No Adverse Events
No signs of hyperproliferation,
abnormal growth, rejection or retinal
detachment.
Persistence of cells
Anatomical evidence of hESC-RPE
survival and engraftment.
Increased pigmentation within the bed
of the transplant.
Impact on Acuity
Recorded functional visual
improvements in both patients.
21. Preliminary Results
21
Persistence of cells
Anatomical evidence of hESC-RPE
survival and engraftment.
Increased pigmentation within the bed
of the transplant.
Engraftment and Survival: SD-OCT image collected at month 3
show survival and engraftment of RPE
23. Preliminary Results
23
Recorded functional visual
improvements in both patients.
• SMD Patient: Best corrected visual
acuity improved from hand
motions to 20/800 and improved
from 0 to 5 letters on the ETDRS
visual acuity chart in the study eye.
• Dry AMD Patient: Vision improved
in the patient with dry age-related
macular degeneration (21 ETDRS
letters to 28).
SMD
Patient
24. Preliminary Results
24
Varying degrees of improvement in visual acuity
across patients
Some patients have pronounced gains in VA
Observed persistence of cell engraftment and
VA gains- 22 months now for initial patients
• Increased letters on ETDRS Charts
• Color perception
• Contrast
• Low light vision
These are very late stage patients with a high degree of
heterogeneity in degree of “rescue-able” photoreceptors
25. Halfway Point
25
Based on safety and functional data from first 18 patients,
FDA and MHRA have approved new 4 patient cohorts in each trial.
Best Vision Inclusion Criteria for new Cohort 2a
includes patients with vision as good as 20/100.
50K Cells 100K Cells 150K Cells 200K Cells
100K CellsFDA and MHRA Approved “Cohort 2a”
Inclusion Criteria: vision 20/100+
27. Phase II/III Projected Timeline
27
Completion of Phase I : 2013-2014
Design of Phase II/III studies is an ongoing process, but
will become more concrete during 2H2013
• Design of future studies dependent upon information
gathered throughout PI/II study
― Efficacy
― Multiple Injections
― Further evaluation of I/E criteria
― Potentially less immunosuppression
Phase II/III study commencement 2014-2015
Working with our
experts/investigators in
design of studies
28. Expanding Clinical Programs
28
Myopia creates a higher risk of permanent vision loss due
to Myopic Macular Degeneration (MMD)
• Severe near-sightedness causes elongation of the eyeball --
which can cause fissures in RPE layer.
January 2013 - FDA Approved
MMD Phase I/II study
Jules Stein Eye Institute (UCLA) and ACT
29. Price Justification
29
Unmet Therapeutic Need
Efficacy
Patient Prevalence
Pharmacoeconomics
Patient Advocacy
Pricing Justification
across all categories
of consideration
…this is what we
believe, now how will
we support this position.
30. Price Justification
30
We understand that reimbursement challenges are
increasingly becoming a central focus for new treatments
• We are working to integrate reimbursement planning early in our
RPE product life cycle
• Addressing reimbursement after market clearance doesn’t work anymore
• Design the right studies the first time…consequences are significant
• Understand payer requirements early; anticipate changes
• Evidence of value is critical; not new…just more pressure
• Value vs. alternatives
• Value to certain patient subpopulations & stakeholders
• Value vs. overall affordability (society, payer, employer & individual)
31. Reimbursement Strategy
31
Conducting a reimbursement analysis and formulating a strategy.
Working to secure meetings with CMS (Medicare) and private
insurers.
Phase II and III: Planning to gather health economics and
comparative clinical effectiveness data.
• Our design of later phases of our trials will include ability to collect and
assess pharmaco-economic data to demonstrate the cost
effectiveness and clinical effectiveness of our RPE product (relative to
existing treatments, if any approved).
Building the case for adequate reimbursement
based on a therapy’s clinical and social
benefits as part of the clinical trials is crucial.
32. Implementation
32
Activity Objectives
Document Unmet
Needs and Clinical
Value
Engaging our KOLs to help us to develop robust arguments that our
RPE cellular therapeutic approach addresses a critical need and is
“good medicine”.
Collect data on
economics of
treatment
Analyzing in detail events, activities, length of time for treatment,
timing and any other associated costs under alternative treatment
scenarios for macular degenerative diseases, particularly dry AMD.
Watching progress of clinical studies using antibodies.
Prepare stakeholder
presentations and
proposals
Documenting disease characteristics, unmet need, current disease
management practices, and measurements of economic impact
Initiate discussions with
stakeholders
Will pursue parallel discussions with CMS, key private payers, and key
treatment centers to build awareness and solicit feedback
Our Strategy during clinical trials….
33. Implementation
33
Activity Objectives
Continue discussions
with providers
We will identify and address hurdles that may remain regarding
institutional review processes and procedures in key treatment
centers – will use our KOLs as necessary.
Engage with
Foundation and Patient
Stakeholders
Develop programs to refer patients, educate patients and families,
and provide reimbursement support, as necessary.
Our Prelaunch Strategy….
34. Implementation
34
Activity Objectives
Support approval and
reimbursement
Provide on-line, phone and in the field support for patient-by-patient
product use and insurance coverage
Our Strategy Post-Launch….
We have some great role
models to follow already…
35. Intellectual Property – RPE Program
Dominant Patent Position for Treating Retinal Degeneration
• Broad Coverage for Manufacturing RPE Cells
• Broad protection of pharmaceutical preparations
Covers both RPE cell suspensions and scaffolded RPE layers.
• RPE Cells derived from other pluripotent stem cells – e.g., iPS cells
o Careful Consideration of Literal Scope
o Preservation of Doctrine of Equivalents
o Constantly Mining Existing Filings
o Vigilantly Filing on Improvements
35
Keeping our
IP Lawyers
on their toes
36. RPE Program - Investment Thesis
36
Dry AMD: More than 50 million patients in major markets.
1% market penetration
may represent $5-10B market opportunity.
Orphan indications: 10% market penetration of SMD alone may be a $100+
million/year product. Orphan status provides options for early authorization.
Immense Unmet
Medical Needs
Small Doses &
Globally Scalable Cold
Chain
Immune Privileged
Injection Site
38. ACT Management Team
Highly Experienced and Tightly Integrated Management Team
Gary Rabin – Chairman & CEO
Dr. Robert Lanza, M.D. – Chief Scientific Officer
Edmund Mickunas – Vice President of Regulatory Affairs
Dr. Irina Klimanskaya, Ph.D. – Director of Stem Cell Biology
Dr. Shi-Jiang (John) Lu, Ph.D. – Senior Director of Research
Dr. Roger Gay, Ph.D. - Senior Director of Manufacturing
Kathy Singh - Controller
Rita Parker – Director of Operations
Dr. Matthew Vincent, Ph.D. – Director of Business Development
Bill Douglass – Dir. of Corporate Communications & Social Media
38
39. Dr. Ronald M. Green: Chairman
Dr. Judith Bernstein
Dr. Jeremy B.A. Green
Dr. Robert Kauffman
Dr. Carol A. Tauer
ACT Leadership
Gary Rabin: Chairman & CEO
Dr. Robert S. Langer, ScD: Prolific medical inventor; Chair – ACT SAB
Gregory S. Perry: EVP – Immunogen
Michael Heffernan: CEO – Collegium Pharma
Zohar Loshitzer: CEO Presbia; Founder LifeAlert Medical
Dr. Alan C. Shapiro: Renowned business school professor
39
World Class Board of Directors
Highly-regarded Ethics Advisory Board